The SFDA's recent approval of Qfitlia for Hemophilia A and B marks a significant milestone in the Saudi Arabia pharmaceutical market. This siRNA-based therapy demonstrates the Kingdom's commitment to adopting innovative, high-efficacy biotechnology.
SFDA Approval of Qfitlia: Saudi Arabia Pharmaceutical Market
By Dina Ibrahim
Category: Market Access
Executive Summary
• The SFDA approval of Qfitlia signals a shift toward siRNA and advanced biologics in Saudi Arabia. • New economic evaluation rules in 2026 will further shape market access requirements. • 83% growth in biotechnology clinical research positions KSA as a regional leader.
Frequently Asked Questions
What is Qfitlia?
An siRNA therapy recently approved by the SFDA to treat Hemophilia A and B by reducing antithrombin levels.